Nieves Martinez Lago
@dramartinezlago.bsky.social
Oncóloga Medica. Tumores digestivos y neuroendocrinos.
Medical Oncologist. Gastrointestinal, neuroendocrine and endocrine tumors. #MedSky #OncSky #NETsSky
Medical Oncologist. Gastrointestinal, neuroendocrine and endocrine tumors. #MedSky #OncSky #NETsSky
Pinned
Reposted by Nieves Martinez Lago
PEM in MSI and dMMR advanced solid tumors - Nieves Martinez Lago
@dramartinezlago.bsky.social
oncodaily.com/science/2541...
#Cancer #CancerResearch #SolidTumor #ClinicalTrial #Medicine #Health #Oncology #OncoDaily
@dramartinezlago.bsky.social
oncodaily.com/science/2541...
#Cancer #CancerResearch #SolidTumor #ClinicalTrial #Medicine #Health #Oncology #OncoDaily
Nieves Martinez Lago: PEM in MSI and dMMR advanced solid tumors - OncoDaily
Nieves Martinez Lago: PEM in MSI and dMMR advanced solid tumors / Aurélien Marabelle, cancer, fight against cancer, Global fight against cancer, Nieves
oncodaily.com
March 11, 2025 at 9:38 PM
PEM in MSI and dMMR advanced solid tumors - Nieves Martinez Lago
@dramartinezlago.bsky.social
oncodaily.com/science/2541...
#Cancer #CancerResearch #SolidTumor #ClinicalTrial #Medicine #Health #Oncology #OncoDaily
@dramartinezlago.bsky.social
oncodaily.com/science/2541...
#Cancer #CancerResearch #SolidTumor #ClinicalTrial #Medicine #Health #Oncology #OncoDaily
Reposted by Nieves Martinez Lago
📢 FDA grants accelerated approval to encorafenib + cetuximab + mFOLFOX6 for treatment-naïve mCRC with BRAF V600E mutation. BREAKWATER trial shows 61% ORR!
Median DoR: 13.9 months. Most common toxicities: neuropathy, nausea, fatigue.
@oncoalert.bsky.social @fda.gov
@oncbrothers.bsky.social
Median DoR: 13.9 months. Most common toxicities: neuropathy, nausea, fatigue.
@oncoalert.bsky.social @fda.gov
@oncbrothers.bsky.social
December 21, 2024 at 6:48 AM
📢 FDA grants accelerated approval to encorafenib + cetuximab + mFOLFOX6 for treatment-naïve mCRC with BRAF V600E mutation. BREAKWATER trial shows 61% ORR!
Median DoR: 13.9 months. Most common toxicities: neuropathy, nausea, fatigue.
@oncoalert.bsky.social @fda.gov
@oncbrothers.bsky.social
Median DoR: 13.9 months. Most common toxicities: neuropathy, nausea, fatigue.
@oncoalert.bsky.social @fda.gov
@oncbrothers.bsky.social
Reposted by Nieves Martinez Lago
Reposted by Nieves Martinez Lago
Is PRRT safe in patients with NETs and extensive bone metastases…? Excellent presentation by Dr. Osama Mosalem at Mayo Florida @nanets.bsky.social 2024. Higher G3/G4 heme tox (29%), some persistent heme tox but no signal of increase in treatment related myeloid neoplasia. #NANETS24 #NETsSky #OncSky
November 22, 2024 at 4:06 PM
Is PRRT safe in patients with NETs and extensive bone metastases…? Excellent presentation by Dr. Osama Mosalem at Mayo Florida @nanets.bsky.social 2024. Higher G3/G4 heme tox (29%), some persistent heme tox but no signal of increase in treatment related myeloid neoplasia. #NANETS24 #NETsSky #OncSky
Reposted by Nieves Martinez Lago
Next big things in #NETs care @cives_mauro at #NANETS24
▪️new PRRT regimens: alpha-emiting RLT
▫️BiTEs for NEC
▪️❓CAR T cell therapy
▫️tumor vaccines 💉
@nanets.bsky.social @oncothor.bsky.social #NETsSky #MedSky
▪️new PRRT regimens: alpha-emiting RLT
▫️BiTEs for NEC
▪️❓CAR T cell therapy
▫️tumor vaccines 💉
@nanets.bsky.social @oncothor.bsky.social #NETsSky #MedSky
November 22, 2024 at 7:31 PM
Next big things in #NETs care @cives_mauro at #NANETS24
▪️new PRRT regimens: alpha-emiting RLT
▫️BiTEs for NEC
▪️❓CAR T cell therapy
▫️tumor vaccines 💉
@nanets.bsky.social @oncothor.bsky.social #NETsSky #MedSky
▪️new PRRT regimens: alpha-emiting RLT
▫️BiTEs for NEC
▪️❓CAR T cell therapy
▫️tumor vaccines 💉
@nanets.bsky.social @oncothor.bsky.social #NETsSky #MedSky
PD-L1 thresholds predict efficacy of ICI in 1L treatment of advanced GEA. A systematic review and meta-analysis of 7 phase III randomized trials
👉Optimal CPS cut-off is uncertain.
👉PD-L1 CPS ≥5 is a good cut-off to predict benefit from ICI.
doi.org/10.1016/j.es...
👉Optimal CPS cut-off is uncertain.
👉PD-L1 CPS ≥5 is a good cut-off to predict benefit from ICI.
doi.org/10.1016/j.es...
November 18, 2024 at 4:48 PM
PD-L1 thresholds predict efficacy of ICI in 1L treatment of advanced GEA. A systematic review and meta-analysis of 7 phase III randomized trials
👉Optimal CPS cut-off is uncertain.
👉PD-L1 CPS ≥5 is a good cut-off to predict benefit from ICI.
doi.org/10.1016/j.es...
👉Optimal CPS cut-off is uncertain.
👉PD-L1 CPS ≥5 is a good cut-off to predict benefit from ICI.
doi.org/10.1016/j.es...
El próximo 29 y 30 de noviembre tendrá lugar la XII Reunión del Grupo Gallego de investigación en Tumores Digestivos @Grupo_GITUD. Os esperamos en a Sede Afundacion de Ferrol.
November 18, 2024 at 4:16 PM
El próximo 29 y 30 de noviembre tendrá lugar la XII Reunión del Grupo Gallego de investigación en Tumores Digestivos @Grupo_GITUD. Os esperamos en a Sede Afundacion de Ferrol.
Late-line options for patients with metastatic colorectal cancer: a review and evidence-based algorithm
👉 FTD/TPI+BEV, REG and FRU for unselected pts
👉 Targeted Therapies for pts With Oncogenic Driver Molecular Alterations
👉Rechallenge antiEGFR in pts ctDNA RAS/BRAFwt
www.nature.com/articles/s41...
👉 FTD/TPI+BEV, REG and FRU for unselected pts
👉 Targeted Therapies for pts With Oncogenic Driver Molecular Alterations
👉Rechallenge antiEGFR in pts ctDNA RAS/BRAFwt
www.nature.com/articles/s41...
Late-line options for patients with metastatic colorectal cancer: a review and evidence-based algorithm - Nature Reviews Clinical Oncology
Over the past few years, several novel therapies, including targeted therapies for specific subgroups as well as several non-targeted therapies, have been developed and approved for patients with chem...
www.nature.com
November 18, 2024 at 4:12 PM
Late-line options for patients with metastatic colorectal cancer: a review and evidence-based algorithm
👉 FTD/TPI+BEV, REG and FRU for unselected pts
👉 Targeted Therapies for pts With Oncogenic Driver Molecular Alterations
👉Rechallenge antiEGFR in pts ctDNA RAS/BRAFwt
www.nature.com/articles/s41...
👉 FTD/TPI+BEV, REG and FRU for unselected pts
👉 Targeted Therapies for pts With Oncogenic Driver Molecular Alterations
👉Rechallenge antiEGFR in pts ctDNA RAS/BRAFwt
www.nature.com/articles/s41...
Reposted by Nieves Martinez Lago
Must read for NET providers - the CommNETs/NANETS statement on NET biomarkers. An extremely useful document, detailing the clinical utility of NET biomarkers after thorough review of the evidence. The short of it is that most are not recommended for routine use.
jamanetwork.com/journals/jam...
jamanetwork.com/journals/jam...
Biomarkers to Inform Prognosis and Treatment for Unresectable or Metastatic GEP-NENs
This study provides a guidance document to educate clinicians and patients on biomarkers informing prognosis and treatment in unresectable or metastatic gastroenteropancreatic neuroendocrine neoplasms...
jamanetwork.com
November 17, 2024 at 5:41 PM
Must read for NET providers - the CommNETs/NANETS statement on NET biomarkers. An extremely useful document, detailing the clinical utility of NET biomarkers after thorough review of the evidence. The short of it is that most are not recommended for routine use.
jamanetwork.com/journals/jam...
jamanetwork.com/journals/jam...
Reposted by Nieves Martinez Lago
You unsure of how to monitor responses in NET patients after PRRT? All these different scans and blood tests confusing? Worry not, this team has you covered...
A must read for all involved in radioligand therapy.
#NETsSky #OncSky
onlinelibrary.wiley.com/doi/10.1111/...
A must read for all involved in radioligand therapy.
#NETsSky #OncSky
onlinelibrary.wiley.com/doi/10.1111/...
<em>Journal of Neuroendocrinology</em> | BSN Journal | Wiley Online Library
Peptide receptor radionuclide therapy (PRRT) is an effective treatment for both oncological and hormone control and is a widely accepted standard of care treatment for patients with neuroendocrine ne...
onlinelibrary.wiley.com
November 17, 2024 at 4:08 PM
You unsure of how to monitor responses in NET patients after PRRT? All these different scans and blood tests confusing? Worry not, this team has you covered...
A must read for all involved in radioligand therapy.
#NETsSky #OncSky
onlinelibrary.wiley.com/doi/10.1111/...
A must read for all involved in radioligand therapy.
#NETsSky #OncSky
onlinelibrary.wiley.com/doi/10.1111/...
Adjuvant NIVO+IPI in pts with resected GC and GEJ following preoperative CT with high risk for recurrence (ypN+ and/or R1): VESTIGE study, phase 3.
👉mDFS nivo+ipi 11.4 vs CT 20.8m (HR 1.55; p=0.99)
👉12mDFS 47.1% vs 64.0%
Give adjuvant FLOT even when there's residual cancer.
doi.org/10.1016/j.an...
👉mDFS nivo+ipi 11.4 vs CT 20.8m (HR 1.55; p=0.99)
👉12mDFS 47.1% vs 64.0%
Give adjuvant FLOT even when there's residual cancer.
doi.org/10.1016/j.an...
November 17, 2024 at 2:41 PM
Adjuvant NIVO+IPI in pts with resected GC and GEJ following preoperative CT with high risk for recurrence (ypN+ and/or R1): VESTIGE study, phase 3.
👉mDFS nivo+ipi 11.4 vs CT 20.8m (HR 1.55; p=0.99)
👉12mDFS 47.1% vs 64.0%
Give adjuvant FLOT even when there's residual cancer.
doi.org/10.1016/j.an...
👉mDFS nivo+ipi 11.4 vs CT 20.8m (HR 1.55; p=0.99)
👉12mDFS 47.1% vs 64.0%
Give adjuvant FLOT even when there's residual cancer.
doi.org/10.1016/j.an...
Ramucirumab/paclitaxel as switch maintenance vs continuation of FOLFOX after 3 months of FOLFOX in HER2-negative GC/GEJ cancer
@TheLancetOncol
doi.org/10.1016/S1470-…
🔎ARMANI phs 3
👉mPFS 6·6 vs 3·5 mo
👉mOS 12·6 vs 10·4 mo
🧐switch maintenance could be an option for pts not eligible for ICI/🎯💊
@TheLancetOncol
doi.org/10.1016/S1470-…
🔎ARMANI phs 3
👉mPFS 6·6 vs 3·5 mo
👉mOS 12·6 vs 10·4 mo
🧐switch maintenance could be an option for pts not eligible for ICI/🎯💊
November 17, 2024 at 2:17 PM
Ramucirumab/paclitaxel as switch maintenance vs continuation of FOLFOX after 3 months of FOLFOX in HER2-negative GC/GEJ cancer
@TheLancetOncol
doi.org/10.1016/S1470-…
🔎ARMANI phs 3
👉mPFS 6·6 vs 3·5 mo
👉mOS 12·6 vs 10·4 mo
🧐switch maintenance could be an option for pts not eligible for ICI/🎯💊
@TheLancetOncol
doi.org/10.1016/S1470-…
🔎ARMANI phs 3
👉mPFS 6·6 vs 3·5 mo
👉mOS 12·6 vs 10·4 mo
🧐switch maintenance could be an option for pts not eligible for ICI/🎯💊
Hi! I’m Dr. Nieves Martínez Lago, a Medical Oncologist focused on GI, NET and endocrine tumors. I’m passionate about sharing knowledge and connecting with other professionals. Looking forward to engaging in insightful discussions and expanding my network. Feel free to reach out! #medsky #oncsky
November 17, 2024 at 9:02 AM
Reposted by Nieves Martinez Lago
Here is a common problem in GI oncology, neuroendocrine differentiation (NED) in non-neuroendocrine carcinoma. According to many studies, outcomes are worse if NED is present (colorectum, esophagus, stomach, lung...). I get asked this often... #NETsSky #OncSky
onlinelibrary.wiley.com/doi/10.1111/...
onlinelibrary.wiley.com/doi/10.1111/...
Neuroendocrine differentiation and serotonin expression in oesophageal adenocarcinomas after neoadjuvant therapy: correlation with clinicopathological features and outcome
Expression of neuroendocrine markers in oesophageal adenocarcinoma after neoadjuvant chemoradiation is independently associated with reduced overall survival. Assessment of neuroendocrine differentia....
onlinelibrary.wiley.com
November 16, 2024 at 4:46 PM
Here is a common problem in GI oncology, neuroendocrine differentiation (NED) in non-neuroendocrine carcinoma. According to many studies, outcomes are worse if NED is present (colorectum, esophagus, stomach, lung...). I get asked this often... #NETsSky #OncSky
onlinelibrary.wiley.com/doi/10.1111/...
onlinelibrary.wiley.com/doi/10.1111/...